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Abstract
Background: Varenicline could affect the T wave and QT interval. The interval from the peak 
to the end of the electrocardiographic (ECG) T wave (Tp-e) may correspond to the transmural 
dispersion of repolarization, and increased Tp-e interval and Tp-e/QT ratio are associated 
with malignant ventricular arrhythmias. In this study, we assessed the effects of varenicline 
on Tp-e interval, Tp-e/QT ratio and Tp-e/QTc ratio.
Methods: Thirty healthy volunteers (15 healthy non-smokers [NS] and 15 healthy smokers 
[S]) were included in the randomized, double-blind, placebo-controlled, crossover study. Varen-
icline (2 mg single dose) or placebo was administered in two different testing sessions (5 days 
after the first period, performed the second period). Tp-e interval, Tp-e/QT ratio and Tp-e/QTc  
ratio were assessed in the supine position and during handgrip exercise before and after the 
participants were given placebo or varenicline. Tp-e interval, Tp-e/QT ratio and Tp-e/QTc 
ratio were calculated from continuous ECG recordings and averages were used in the final 
analysis.
Result: There were no statistically significant differences among any of the Tp-e interval, 
Tp-e/QT ratio and Tp-e/QTc ratio before and after placebo administration in both groups  
(S and NS). In the S group, Tp-e and QTc interval, and Tp-e/QT and Tp-e/QTc ratio were 
significantly increased after varenicline administration (Tp-e: 64.28 ± 8.78 vs. 70.42 ±  
± 13.12; p = 0.02, QTc: 409.57 ± 28.17 vs. 425.28 ± 32.79; p = 0.02, Tp-e/QT: 0.18 ± 0.02 vs.  
0.19 ± 0.03; p = 0.04, Tp-e/QTc: 0.17 ± 0.02 vs. 0.19 ± 0.02; p = 001) but these parameters 
were not changed in the NS group.
Conclusions: Tp-e and QTc interval, and Tpe/QT and Tpe/QTc ratio were increased after 
varenicline administration in smokers. (Cardiol J 2015; 22, 5: 551–556)
Key words: varenicline, Tp-e interval, QT interval
Introduction
Cigarette smoking is a major cardiovascular 
risk factor for atherosclerotic diseases [1]. Among 
smokers with coronary heart disease, smoking 
cessation is associated with a 36% reduction of the 
risk of mortality due to all causes, making smoking 
cessation fundamental to secondary prevention of 
cardiovascular disease [2, 3].
Pharmacotherapy is a standard component 
of evidence-based smoking cessation treatment 
[4]. One of the pharmacological agents used for 
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smoking cessation treatment is varenicline. Vareni-
cline is an a4b2 nicotinic acetylcholine receptor 
(nAChR) partial agonist [5, 6]. As varenicline has 
this partial agonistic action, it may cause relief of 
the withdrawal and craving symptoms associated 
with nicotine.
Ventricular repolarization is commonly as-
sessed using QT interval and T wave measure-
ments. Recent studies indicated that the Tp-e 
interval, which is the interval between the peak 
and the end of the T wave on an electrocardio-
gram (ECG), can be used as an index of the total 
(transmural, apico-basal, global) dispersion of re-
polarization [7, 8]. Increased Tp-e interval might 
be also a useful index to predict ventricular tachy-
arrhythmias and cardiovascular mortality [9–11].
Changes in the autonomic tone modulate 
QT duration, and the prolonged QT interval is 
regarded as a marker of imbalanced distribution 
of sympathetic nervous system activity on the 
heart. Varenicline could affect the autonomic 
cardiovascular system by binding to a3b4 nAChR 
and a7 nAChR. The effect of varenicline on QT 
interval and T wave measurements has not been 
studied. We have recently published a randomized, 
placebo controlled and crossover trial about the 
acute effects of varenicline on heart rate vari-
ability parameters [12], and we reanalyzed the 
study data to test the acute effects of varenicline 
on QT and Tp-e interval, and Tp-e/QT and Tp-e/ 
/QTc ratio in healthy smokers (S) and nonsmokers 
(NS). The goal of our study was to test hypothesis 
if administration of high dose of varenicline was 
(not) associated with changes in repolarization 
among healthy S and NS. Our secondary goal was 
to assess differences in varenicline induced repo-
larization changes between S and NS. Our tertiary 
goal was to assess for non-repolarization related (or 
non-cardiovascular) side-effect of administration of 
high dose varenicline.
Methods
Subjects
Thirty healthy volunteers with a mean age of 
28.23 ± 1.46 years (range 24–33 years, 16 male, 
14 female) were studied in a randomized, double-
-blind, placebo-controlled, crossover design study. 
Fifteen healthy NS and 15 healthy S were included 
in the study after providing their written informed 
consent in accordance with the study protocol ap-
proved by the Ethical Committee of our hospital. 
All subjects had normal standard ECGs and no 
structural heart disease as documented by medical 
history, physical examination, and echocardiogra-
phy. No subject was taking any medication or had 
any history of a chronic disease.
Study design and electrocardiographic 
measurements
All participants were asked to refrain from 
alcohol, cigarette smoking and caffeine-containing 
beverages as well as strenuous exercise for 24 h 
prior to each study session. All subjects had a light 
breakfast after an overnight period of fasting and 
were taken to a quiet, dimly lit room maintained 
at 22– 24°C. The studies were performed between 
09:00 am and 02:00 pm to avoid circadian variations 
in ECG parameters. All participants were taken 
to the test room and allowed to rest in the supine 
position for at least 15 min on a comfortable bed 
to stabilize heart rate. After this resting period, 
continuous ECG recordings (ECGs were recorded 
at a sampling rate of 200 Hz using a Spiderview™ 
recorder) were performed in the supine position 
for 10 min. After this recording period, ECG re-
cording performed at sitting position for 10 min 
during handgrip exercise. Participants performed 
isometric handgrip exercise at 25% of their pre-
determined maximum voluntary capacity by 45 s 
contraction and 15 s rest per minute using a Sae-
han hydraulic hand dynamometer (SH5001, Seoul, 
Korea). The 10 min handgrip exercise procedure 
repeated three times and the averages of total rest 
and handgrip exercise period were used in the 
final analysis. After baseline data were obtained, 
subjects were orally administered varenicline 
(2 mg) or placebo. The order of administration of test 
drug or placebo was randomized, and subjects were 
blinded to whether they received the test drug or 
the placebo. Three hours after use of varenicline 
or placebo, the participants once again underwent 
the same procedures described above. Blood 
pressure measurements were obtained from the 
left arm supported at heart level by a nurse using 
a sphygmomanometer prior to and after each period. 
Previously, it had been shown that the elimination 
half-life of varenicline is nearly 24 h [13]. Five days 
after (total varenicline elimination time) the first 
testing period, the participants were reassigned 
to the opposite group (varenicline or placebo 
group) and again underwent the same procedures 
described above.
Tp-e interval, Tp-e/QT ratio and Tp-e/QTc 
ratio were calculated from continuous ECG record-
ings (ECGs were recorded at a sampling rate of 
200 Hz using a Spiderview™ recorder). Record-
ings were analyzed on a Synescope™ system. We 
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measured the QT, RR and Tp-e intervals in lead II. 
We measured the QT interval from the beginning 
of the QRS complex to the end of the T wave and 
the Tp-e interval from the peak of the T wave to 
the end of the T wave, defined as the point of re-
turn to the T–P baseline. If U waves were present, 
we defined the end of the T wave as the nadir of 
the curve between the T and U waves. The QT 
intervals were corrected according to the formula 
of Bazett, where (QTc = QT / ÷ RR) [14].
Statistical analysis
Statistical analyses were performed with the 
SSPS 10.0 software package (SPSS Inc., Chicago, IL). 
All numeric variables are expressed as the 
mean ± standard deviation, and categorical vari-
ables are expressed as percentages. The normal 
distribution suitability of the groups was assessed 
using the Shapiro-Wilk test. According to the 
Shapiro-Wilk test only the placebo period Tp-e 
(mean) value is not distributed normally, other 
parameters distribute normally. Because of the 
result we used nonparametric tests. Inter-group 
comparisons were made by the Mann-Whitney 
U test (for continuous variables), and categorical 
variables were compared by the c2 test or Fisher’s 
exact test. The repeated measurements (before and 
after varenicline or placebo) were analyzed with the 
Wilcoxon signed rank test. A p-value < 0.05 was 
considered statistically significant.
Results 
Baseline characteristics of the S and NS groups 
are shown in Table 1. Echocardiographic examina-
tion revealed no significant cardiac disorder and 
normal left ventricular ejection fraction.
There were no statistically significant differ-
ences among any of the QT, QTc and Tp-e interval, 
Tp-e/QT and Tp-e/QTc ratio before and after pla-
cebo or varenicline administration, between the 
S and NS group (p > 0.05) (Table 2). In the S group 
QTc (409.57 ± 28.17 vs. 425.28 ± 32.79; p = 0.02), 
Tp-e interval (64.28 ± 8.78 vs. 70.42 ± 13.12; 
p = 0.02), Tp-e/QT (0.18 ± 0.02 vs. 0.19 ± 0.03; 
p = 0.04) and Tp-e/QTc ratio (0.17 ± 0.02 vs. 
0.19 ± 0.02; p = 0.01) were significantly increased 
after varenicline administration but these param-
eters were not change in the NS group (Table 3).
Adverse events
Nausea and vomiting (NS: 7 [46.7%] vs. S: 1 
[6.7%]; p = 0.01), dizziness (NS: 6 [40%] vs. S: 1 
[6.7%]; p = 0.03) and hypotension (NS: 4 [26.7%] 
vs. S: –; p = 0.03) were significantly more fre-
quent in the NS group than in the S group. The 
palpitation rate and the incidence of sweating were 
similar in both the S and NS groups (p > 0.05). At 
the Holter recording ventricular extrasystole was 
significantly more frequent in the NS group than 
in the S group (NS: 4 [26.7%] vs. S: –; p = 0.03), 
however supraventricular extrasystole was similar 
in both groups (Table 4).
Discussion
The principal findings of the analysis are; first, 
the repolarization parameters were not different 
before and after the administration of high dose of 
varenicline in between healthy S and NS, second, 
the repolarization parameters were significantly 
changed before and after the administration of high 
dose of varenicline in S however it was not sig-
nificantly changed in NS, third, non-cardiovascular 
side-effects were significantly higher in the NS 
than in the S with a single high dose of varenicline.
A single high dose of varenicline did not affect 
the QT and Tp-e interval, Tp-e/QT and Tp-e/QTc 
Table 1. Baseline characteristics of nonsmokers and smokers.
Nonsmoker (n = 15) Smoker (n = 15) P
Age [year] 28.20 ± 2.67 28.26 ± 2.57 0.94
Gender (male/female) 8 (53.3%)/7 (46.7%) 8 (53.3%)/7 (46.7%) 1
BMI [kg/m2] 24.33 ± 3.41 22.60 ± 2.10 0.10
Heart rate [bpm] 80.46 ± 6.79 82.01 ± 6.32 0.52
SBP [mm Hg] 113.33 ± 9.75 116.07 ± 11.83 0.50
DBP [mm Hg] 66.66 ± 6.17 69.33 ± 11.62 0.43
LVEF [%] 66.86 ± 1.18 67.33 ± 1.67 0.38
Cigarette smoking (pack-years) 10.2 ± 2.1 – < 0.001
BMI — body mass index; DBP — diastolic blood pressure; SBP — systolic blood pressure; LVEF — left ventricular ejection fraction
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Table 3. Tp-e, QT parameters in nonsmokers and smokers before and after varenicline.
Smokers (n = 15) Before varenicline After varenicline P 
QT 357.57 ± 20.75 357.14 ± 21.62 0.93
QTc 409.57 ± 28.17 425.28 ± 32.79 0.02
Tp-e (mean) 64.28 ± 8.78 70.42 ± 13.12 0.02
Tp-e/QT 0.18 ± 0.02 0.19 ± 0.03 0.04
Tp-e/QTc 0.17 ± 0.02 0.19 ± 0.02 0.01
Nonsmokers (n = 15) Before varenicline After varenicline P 
QT 367.00 ± 23.66 357.18 ± 23.24 0.28
QTc 422.63 ± 12.05 423.09 ± 15.28 0.62
Tp-e (mean) 72.45 ± 7.82 71.43 ± 14.11 0.88
Tp-e/QT 0.19 ± 0.08 0.20 ± 0.02 0.44
Tp-e/QTc 0.18 ± 0.09 0.20 ± 0.03 0.29
Table 2. Tp-e, QT parameters in nonsmokers and smokers with placebo and varenicline.
Nonsmokers  
(n = 15)
Smokers  
(n = 15)
P Nonsmokers  
(n = 15)
Smokers  
(n = 15)
P 
Before placebo Before varenicline
QT 363.28 ± 19.12 374.50 ± 44.27 0.61 367.00 ± 23.66 357.57 ± 20.75 0.41
QTc 421.00 ± 12.51 446.83 ± 60.82 0.31 422.63 ± 12.05 409.57 ± 28.17 0.36
Tp-e (mean) 69.71 ± 5.21 65.83 ± 10.14 0.15 72.45 ± 7.82 64.28 ± 8.78 0.07
Tp-e/QT 0.19 ± 0.02 0.17 ± 0.09 0.19 0.19 ± 0.08 0.18 ± 0.02 0.41
Tp-e/QTc 0.17 ± 0.05 0.15 ± 0.08 0.39 0.18 ± 0.09 0.17 ± 0.02 0.21
After placebo After varenicline
QT 379.71 ± 33.97 387.66 ± 49.68 0.66 357.18 ± 23.24 357.14 ± 21.62 0.92
QTc 442.42 ± 55.30 452.50 ± 74.01 0.52 423.09 ± 15.28 425.28 ± 32.79 0.71
Tp-e (mean) 66.02 ± 13.87 63.00 ± 7.64 0.24 71.43 ± 14.11 70.42 ± 13.12 0.55
Tp-e/QT 0.17 ± 0.03 0.16 ± 0.02 0.39 0.20 ± 0.02 0.19 ± 0.03 0.44
Tp-e/cQT 0.15 ± 0.06 0.14 ± 0.05 0.31 0.20 ± 0.03 0.19 ± 0.02 0.29
Table 4. Adverse events in nonsmokers and smokers with varenicline.
Nonsmokers (n = 15) Smokers (n = 15) P 
Nausea and vomiting 7 (46.7%) 1 (6.7%) 0.01
Dizziness 6 (40%) 1 (6.7%) 0.03
Sweating 3 (20%) – 0.06
Palpitation 1 (6.7%) 1 (6.7%) 1
Hypotension 4 (26.7%) 0 (0%) 0.03
Supraventricular extrasystole 1 (6.7%) 2 (13.3%) 0.54
Ventricular extrasystole 4 (26.7%) 0 (0%) 0.03
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ratio in the NS group and increased QTc and 
Tp-e interval, Tp-e/QT and Tp-e/QTc ratio in the 
S group.
Tp-e interval and Tp-e/QT ratio have been 
used as new ECG markers of the increased dis-
persion of ventricular repolarization, prolongation 
of the Tp-e interval is related with ventricular 
arrhythmia and sudden cardiac death [7–11]. Elec-
trophysiological studies showed that a prolonged 
Tp-e interval was associated with ventricular 
tachycardia induction and the spontaneous occur-
rence of ventricular tachycardia [9, 10]. However, 
the Tp-e/QT ratio is considered to be a more sen-
sitive index of arrhythmogenesis compared with 
the sole use of either the Tp-e or QT intervals, as 
it is not affected by variations in body weight and 
heart rate [7]. This improves the signal-to-noise 
ratio, and provides more distinctive information 
to predict arrhythmogenesis [7]. Higher Tp-e/QT 
ratio has been associated with arrhythmic events 
in many clinical conditions, such as Brugada syn-
drome, hypertrophic cardiomyopathy, and acute 
myocardial infarction [7, 9–11].
In our study, we showed that single high dose 
(2 mg) varenicline increased Tp-e interval, and 
Tp-e/QT, Tp-e/QTc ratio in the smokers. On the 
other hand, smoking is one cause of the increased 
Tp-e, QT interval and Tp-e/QT, Tp-e/QTc ratio 
[15]. When considered from this point of view, 
when varenicline is usedto make smokers quit 
smoking, they should evaluate if they had a prear-
rhythmic state or not.
Experimental studies showed that high dose 
of varenicline could decrease or not change the 
QT and QTc duration [13, 16]. In our study, the 
QT duration was not changed significantly with 
single dose of varenicline, however QTc duration 
increased significantly. However, in that study, QTc 
was measured with the Fridericia’s formula [17]. 
The different evaluation formula could explain the 
differences.
However, recent studies and meta-analysis 
showed that the cardiac effect of varenicline was 
similar with placebo but Tp-e, Tp-e/QT and Tp-e/QTc 
parameters were not evaluated in that analysis 
[18]. In our study, Tp-e interval and QTc duration 
were significantly increased. This result could be 
associated with a single high dose of varenicline ad-
ministration, on the other hand, smoking cigarettes 
and exercise itself could prolong the QTc duration 
[15, 19]. For smoking cessation, the drug started 
with low dose and increased to 1 mg twice a day, 
not single 2 mg dose. Tp-e and QT parameters were 
not significantly changed before and after placebo 
and the baseline parameters were similar in both 
groups except for cigarette smoking so the combi-
nation effect of cigarette smoking and varenicline 
could explain the electrocardiographic changes.
Limitations of the study
This study is a sub-study of the “The effect 
of varenicline on heart rate variability in healthy 
smokers and nonsmokers”. The present study in-
cluded only a small number of healthy volunteers, 
and only short-term records were obtained. The 
patients were all young males and females, and 
most of the people using varenicline for treatment 
of smoking cessation are older than the participants 
in our study. Therefore, our results do not reflect 
the overall effects of the varenicline on ECG in-
terval, and the results may not be completely gen-
eralized to all smoking patients. We administered 
only a single high dose of the drug, so we could 
not evaluate the long-term and the standard dose 
effects of varenicline.
Conclusions
Our study showed that Tp-e interval, Tp-e/QT 
ratio and Tp-e/QTc ratio increased after varenicline 
administration in smokers. The association be-
tween parameters of ventricular arrhythmogenesis 
and varenicline treatment needs to be confirmed 
by larger-scale studies.
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